Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
Tarik Silk, Mikhail Silk, Jennifer Wu
Abstract
Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in this disease stage. Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease. The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients. We will focus on "the up to seven" criteria and its utility in selecting systemic therapy.
Topics & Concepts
Systemic therapyHepatocellular carcinomaMedicineStage (stratigraphy)DiseaseLiver diseaseSystemic diseaseInternal medicineLiver cancerOncologyCarcinomaCancerBiologyPaleontologyBreast cancerHepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentLiver physiology and pathology